Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2023, 2025.
Financials
Financial year 2025
A. JANS PHARMA from Bree, company number BE0754509847, closed financial year 2025 with a result of € 70,324 after tax. For that financial year A. JANS PHARMA recorded a gross margin of € 52,125 and equity of € 926,036. Compared with financial year 2024, the result moved from € 66,538 to € 70,324. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ 926,036
▲ 72% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 70,324
▲ 6% vs 2024
Profit after tax over the fiscal year.
€ 217,622
▲ € 210,753 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 849,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 2,016
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 129
▼ 88% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,339
▼ 79% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 122,887 | € 121,478 | € 122,547 | € 52,125 | ▼ 57% |
| Profit after taxes | € 91,847 | € 92,225 | € 66,538 | € 70,324 | ▲ 6% |
| Equity | € 379,880 | € 472,104 | € 538,643 | € 926,036 | ▲ 72% |
| Total debts | € 953,150 | € 842,889 | € 744,048 | € 105,046 | ▼ 86% |
| Cash | € 45,962 | € 34,595 | € 6,869 | € 217,622 | ▲ € 210,753 |
| Retained profit | € 203,880 | € 296,104 | € 362,643 | € 750,036 | ▲ 107% |
| Dividend | € 0 | € 0 | € 0 | € 849,000 | |
| Bank debt | € 838,639 | € 728,748 | € 618,061 | € 0 | ▼ 100% |
| Balance sheet total | € 1,333,030 | € 1,314,993 | € 1,282,691 | € 1,031,081 | ▼ 20% |
Key figures of A. JANS PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to A. JANS PHARMA?
What happened at A. JANS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
- New establishment in Bree. KBO
- Andrea Jans became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 91,847 profit in 2022 to € 70,324 profit in 2025.
Paid € 75,791 in corporate taxes since 2022.
Best year ever: 2023, with € 92,225 profit.
Paid out € 849,000 in dividends to the owners in total.
Management
Behind A. JANS PHARMA is Andrea Jans. Andrea Jans is also behind met Apotheken and Het Apothekershuis.
Directors
According to the 2025 annual accounts
since 2020
Establishments
Establishment units
Physical locations of this company
Kloosterstraat 11
3960 Bree
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0754.509.847
- VAT number
- BE 0754.509.847
- Registered office
- Kloosterstraat 11, 3960 Bree
- Names & denominations
- A. JANS PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 September 2020
- Peppol
- Active · Active since 13 Jan 2026
- Activities · NACE
Activiteiten van holdings
Holdings